CC
VNDA icon

Centiva Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Centiva Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,800
Closed -$101K – 2634
2024
Q2 		$101K Buy
+17,800
New +$91.9K ﹤0.01% 1852

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Centiva Capital's VNDA Position: Q4 2023 in Review

Centiva Capital sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 33,021 shares — an estimated $143K sold.

Centiva Capital first reported a position in VNDA in Q3 2023 and held it in 1 quarter. The position peaked at $143K in Q3 2023. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

  • Centiva Capital reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Centiva Capital sold 33,021 Vanda Pharmaceuticals shares in Q4 2023, an estimated $143K.
  • Centiva Capital first reported a position in Vanda Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Centiva Capital's Vanda Pharmaceuticals position peaked at $143K in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Centiva Capital's 13F filing for Q4 2023, filed 14 Feb 2024.